Correlation Between Krystal Biotech and Sarepta Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and Sarepta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and Sarepta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Krystal Biotech and Sarepta Therapeutics, you can compare the effects of market volatilities on Krystal Biotech and Sarepta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of Sarepta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and Sarepta Therapeutics.

Diversification Opportunities for Krystal Biotech and Sarepta Therapeutics

0.4
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Krystal and Sarepta is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and Sarepta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sarepta Therapeutics and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with Sarepta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sarepta Therapeutics has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and Sarepta Therapeutics go up and down completely randomly.

Pair Corralation between Krystal Biotech and Sarepta Therapeutics

Given the investment horizon of 90 days Krystal Biotech is expected to generate 1.35 times more return on investment than Sarepta Therapeutics. However, Krystal Biotech is 1.35 times more volatile than Sarepta Therapeutics. It trades about -0.05 of its potential returns per unit of risk. Sarepta Therapeutics is currently generating about -0.2 per unit of risk. If you would invest  20,051  in Krystal Biotech on August 24, 2024 and sell it today you would lose (1,822) from holding Krystal Biotech or give up 9.09% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Krystal Biotech  vs.  Sarepta Therapeutics

 Performance 
       Timeline  
Krystal Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Krystal Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Sarepta Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Krystal Biotech and Sarepta Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Krystal Biotech and Sarepta Therapeutics

The main advantage of trading using opposite Krystal Biotech and Sarepta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, Sarepta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarepta Therapeutics will offset losses from the drop in Sarepta Therapeutics' long position.
The idea behind Krystal Biotech and Sarepta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.